Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro

Psychopharmacology

Volumn 151, Issue 4, 2000, Pages 312-320

  Stormer, E ^a   Brockmoller, J ^a   Roots, I ^a   Schmider, J ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cytochrome P 450; FMO; Human; In vitro drug metabolism; Perazine

Indexed keywords

ALPHA NAPHTHOFLAVONE; ALPRAZOLAM; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DIMETHYLANILINE MONOOXYGENASE; KETOCONAZOLE; NEUROLEPTIC AGENT; OMEPRAZOLE; PARACETAMOL; PERAZINE; PHENACETIN; QUINIDINE; SULFAPHENAZOLE; THIAMAZOLE; TOLBUTAMIDE;

ARTICLE; DEMETHYLATION; DRUG DISPOSITION; DRUG OXIDATION; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXYGENASES; PERAZINE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0033833537     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000489     Document Type: Article

References (46)

1. Interpretation of blood and tissue concentrations in fatal self-ingested overdose involving amitriptyline: An update (1978-1979)
2. Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain
3. Allelic and functional variability of cytochrome P450 2C9
4. Metabolism of thioridazine by microsomal monooxygenases: Relative roles of P450 and flavin-containing monooxygenase
5. Pharmacological studies on perazine and its primary metabolites
6. Urinary metabolites of 10-[3'-(4'-methyl-piperazinyl)-propyl]-phenothiazine (perazine) in psychiatric patients. I. Isolation, identification and determination of metabolites
7. Metabolism of perazine in vitro
8. Metabolism of the phenothiazine drug perazine by liver and lung microsomes from various species
9. Accumulation and elimination of a novel metabolite during chronic administration of the phenothiazine drug perazine to rats
10. Measurement of plasma levels of tricyclic psychoactive drugs and their metabolites by UV reflectance photometry of thin layer chromatograms
11. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data
12. Single-dose kinetics of the neuroleptic drug perazine in psychotic patients
13. Plasma protein binding of perazine and amitriptyline in psychiatric patients
14. Cytochrome P450 2D6 genotype partially explains interindividual pharmacokinetic variability of perazine and desmethylperazine
15. Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans
16. Xenobiotic metabolising human cells as tools for pharmacological and toxicological research
17. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions
18. Pharmacokinetic interaction between imipramine and antidepressant neuroleptics in rats
19. Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged treatment in rats
20. Fatal poisoning with clozapine and perazine. A case report
21. A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes
22. Urinary metabolites of 10-(3'-(4'-methyl-piperazinyl)-propyl)-phenothiazine (perazine) in psychiatric patients. II. Individual metabolite patterns and their changes in the course of treatment
23. Identification of a urinary metabolite of perazine as a piperazine-2,5-dione derivative
24. Cytochrome P450 2C9: An enzyme of major importance in human drug metabolism
25. Fitting curves to data using nonlinear regression: A practical and nonmathematical review
26. Serumspiegel von perazin und seinen metaboliten: Qualitatskontrolle, kosten, interpretation und praktische bedeutung
27. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
28. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
29. Changes in drug elimination under the influence of perazine therapy
30. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients
31. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
32. Binding of perazine to alpha 1-acid glycoprotein
33. Metabolism and excretion of the neuroleptic drug perazine in healthy volunteers
34. Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to amitriptyline N-demethylation
35. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies
36. Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics, evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine
37. Recent trends in prescribing psychotropic drugs at a psychiatric university hospital (1981-84)
38. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
39. N-Oxygenation of clozapine by flavin-containing monooxygenase
40. Alprazolam metabolism in vitro: Studies of human, monkey, mouse and rat liver microsomes
41. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo
42. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole
43. In vitro approaches to predicting drug interactions in vivo
44. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
45. Flavin-containing monooxygenases: Catalytic mechanism and substrate specificities